B16-F1 Syngeneic Model Service for Melanoma

The B16-F1 syngeneic model service for melanoma is an immune-competent C57BL/6 platform built on the first selection cycle of Fidler’s historic F-series — a pigmented, low-metastatic melanoma line that remains the field’s most demanding test for immunotherapy, vaccination, and adoptive cell-therapy constructs. Alfa Cytology delivers this model as a complete preclinical capability — covering authenticated B16-F1 / luciferase-labeled B16-F1 expansion with the line’s documented stability controls, subcutaneous or experimental-metastatic implantation, scheduled caliper and in vivo imaging monitoring, and full melanoma histopathology with differentiation-antigen and checkpoint immunophenotyping — all configured around each sponsor’s vaccine, checkpoint, ACT, or combination hypothesis.

Overview of B16-F1 Syngeneic Model for Melanoma

B16 is where modern metastasis research began. The parental tumor arose spontaneously in 1954 in the skin behind the ear of a C57BL/6 mouse at the Jackson Laboratory, and in 1973 Isaiah Fidler turned it into one of the most consequential experimental systems in oncology: he isolated ten single-cell clones — B16-F1 through B16-F10 — and asked, in a deliberate homage to the Luria–Delbrück experiment, whether metastatic ability pre-exists in rare cells or is acquired at distant sites. Tail-vein challenges showed wildly different lung-colonizing efficiencies among the clones, proving that metastatic variants pre-exist — and Fidler & Kripke’s 1977 Science paper went on to show that repeated in vivo selection of lung-colonizing cells yields ever more aggressive derivatives. B16-F1 is the product of a single selection cycle and carries the series’ low metastatic potential (in contrast to the ten-cycle, aggressively metastatic B16-F10), making it the subline of choice when primary-tumor growth and localized tumor behavior are the questions rather than metastatic spread. The line is pigmented (a genuine melanin producer), grows with a 22-hour doubling time, and presents the immunological face of B16 that has defined its reputation: low, interferon-γ-inducible MHC class I expression, weak intrinsic immunogenicity, and a stubborn unresponsiveness to adoptive CTL treatment of subcutaneous disease — properties that prompted the authoritative review to call B16 treatment “a rigorous test for immunotherapy of murine cancer.”

Fig 1. DC-based vaccination efficacy in the B16-F1 syngeneic melanoma model. (Mac Keon, Soledad, et al., 2019)

That reputation is precisely what makes B16-F1 so heavily used. The line expresses the full panel of melanoma differentiation antigens — gp100/pmel, tyrosinase, TRP-1, and TRP-2 (including the H-2D^b-restricted TRP-2 epitope SVYDFFVWL) — which has made it the substrate for virtually every major immunotherapy paradigm: GVAX-style B16.GM-CSF vaccines; recombinant viral vectors encoding TRP-1 that simultaneously protect against tumor and induce vitiligo as a visual readout of antigen-directed autoimmunity; cytomegalovirus-based TRP-2 vaccines that reject established tumors; and the standard adoptive cell-therapy protocol pairing sublethal irradiation with pmel-1 transgenic T cells and interleukin-2. In vivo behavior is famously consistent when technique is disciplined — subcutaneous doses of 1–5 × 10⁵ cells produce palpable tumors in five to ten days and 1 cm × 1 cm masses in two to three weeks — and the field has developed complementary readouts from caliper and bioluminescence imaging (luciferase-engineered B16-F1 derivatives are commercially established) to gp100/TRP-2 triplex qPCR quantification of lung burden. One operational truth about B16 deserves emphasis: the line is unstable, with pigmentation, minimal tumorigenic dose, metastatic potential, antigen expression, and CTL recognition all documented to drift between laboratories and over time — so large frozen banks of the validated working line, thawed fresh for each study, are the price of interpretable results. The reward is a melanoma platform whose seventy-year history of benchmarking makes every new result immediately comparable to the field’s deepest dataset.

Cell Line Information: B16-F1

The table below consolidates the key biological, cultural, and modeling characteristics of the B16-F1 line and its engineered derivatives.

Our Services

A line this historic is only as trustworthy as the bank behind it, and Alfa Cytology runs B16-F1 with the discipline the field’s deepest dataset demands: large validated frozen banks with scheduled fresh-thaw cycles and documented stability monitoring, meticulous subcutaneous technique, all three burden-readout modalities (caliper, bioluminescence, gp100/TRP-2 qPCR), and endpoint pathology tuned to melanoma — all under one accountable preclinical operation.

Workflow of B16-F1 Syngeneic Model Construction

Construction follows the authoritative B16 methodology: B16-F1 or luciferase-labeled cells are expanded under authenticated, stability-controlled conditions, implanted subcutaneously or intravenously into C57BL/6 mice, grown to a standardized baseline, randomized, treated, and analyzed with melanoma-appropriate efficacy and immune endpoints. The workflow comprises the following stages.

1. Cell authentication and banking: B16-F1 or reporter derivatives are identity-verified, confirmed mycoplasma-negative, checked for pigmentation and antigen-expression fidelity, and expanded into large validated frozen banks with scheduled fresh-thaw cycles to guard against the line’s documented drift.
2. Cell harvest and formulation: Healthy cultures are trypsinized, washed, counted and viability-checked, then resuspended at the study-specified dose of 1 × 10⁵ to 5 × 10⁵ cells (subcutaneous) or per validated metastatic protocol in 100 μL of PBS.
3. Anesthesia and implantation: C57BL/6 mice are anesthetized with isoflurane; cells are implanted subcutaneously into the flank with a verified injection bleb (a documented quality determinant) or injected intravenously via tail vein for experimental metastasis arms.
4. Establishment monitoring and randomization: Tumors are measured by caliper from first palpability (5–10 days); luciferase arms are imaged after luciferin administration; animals are randomized once tumors reach protocol-specified baselines, before ulceration or central necrosis.
5. Treatment administration: Experimental arms — vaccines, checkpoint inhibitors, adoptive pmel-1 or engineered T-cell transfer with the 5 Gy irradiation/IL-2 conditioning standard, targeted agents, radiation, and combinations — proceed per study design with body-weight and toxicity monitoring.
6. Longitudinal monitoring and immune assays: Caliper or imaging sessions track growth kinetics; antigen-specific CD8⁺ T-cell responses are quantified by TRP-2 (SVYDFFVWL) and gp100 tetramers, intracellular cytokine staining, and ELISPOT; vitiligo is scored where antigen-directed autoimmunity is a readout.
7. Endpoint and histopathological analysis: Endpoints integrate tumor-growth inhibition, survival, and — for metastatic arms — lung burden by surface counts, bioluminescence, or gp100/TRP-2 triplex qPCR, with histopathology (H&E confirming pigmented melanoma, plus gp100, TRP-2, Ki67, CD8, and PD-L1 immunohistochemistry) and terminal immune-context profiling.

Fig 2. B16-F1 Syngeneic Model construction workflow.

Case Study-B16-F1 Syngeneic Model Development

Alfa Cytology has conducted preclinical programs on the B16-F1 platform spanning vaccine and checkpoint evaluation, pmel-1 adoptive-therapy benchmarking, and primary-tumor-growth studies using the low-metastatic F1 phenotype with B16-F10 matched controls. In these studies, implanted B16-F1 tumors were monitored through scheduled caliper and in vivo imaging measurements, treated per randomized regimens, and characterized at endpoint by histopathology with differentiation-antigen and checkpoint immunophenotyping. Study-level datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology pairs historic-line stewardship with melanoma-immunology expertise, so every B16-F1 study is executed against the platform’s documented drift risks with matched F10 controls and antigen-specific immune readouts.

• Focused experience with the Fidler F-series, including F1-versus-F10 matched design and stability-controlled banking.
• A single coordinated team managing cell banking, implantation, adoptive-transfer logistics, in vivo imaging, and endpoint pathology under one quality framework.
• Fluency with vaccine, checkpoint, and ACT formats, including the 5 Gy/IL-2 conditioning standard and vitiligo readouts.
• Three complementary burden modalities — caliper, bioluminescence, and gp100/TRP-2 triplex qPCR — enabling metastatic-arm quantification at any scale.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your melanoma program needs the field’s most demanding immunotherapy test — with F10-matched metastatic control and melanin-differentiated antigen readouts — Alfa Cytology is ready to build the study around your construct. Reach out to us with your regimen and endpoint requirements, or contact us today for a customized proposal and quotation for the B16-F1 syngeneic model service.

For research use only. Not intended for any clinical use.